Sasaki, N., Suezawa, T., Kitano, S., Katayama, R. and Matsusaki, M. Hierarchical collagen nanofiber gels recapitulate a physiologically relevant tumor stromal microenvironment.
Adv. Healthc. Mater., e00877 (2026) |
Sakahara, M., Okamoto, T., Kumegawa, K., Natsume, Y., Kusama, D., Yamanaka, H., Komatsuzaki, R., Yaginuma, K., Srivastava, U., Takahashi-Kanemitsu, A., Susaki, E. A., Obama, K., Nagayama, S., Maruyama, R. and Yao, R. Colorectal cancer co-opts an epidermal wound healing program during metastasis to generate disseminated tumor cells.
Nat. Commun., in press (2026) |
Noda, T., Shirahama, H., Tani, Y. and Tomida, A. Pharmacological blockade of oncogenic MAPK activators drives resistance to cystine deprivation with lipid redox remodeling.
Biochem. Biophys. Res. Commun., 832, 154376 (2026) |
Yoshitake, H., Negoto, T., Moritsubo, M., Furuta, T., Jo, M., Hirota, T., Sakata, K., Nakamura, H. and Morioka, M. Chromosomal instability is associated with paradoxical cGAS upregulation and impaired STING signaling shaping the immune microenvironment in glioblastoma.
Neurooncol. Adv., vdag179 (2026) |
Hara, T., Meng, S., Konno, M., Nishida, N., Koseki, J., Meguro, K., Kawano, Y., Morie, T., Dan, S., Satoh, T., Akai, S., Tsujikawa, K., Eguchi, H., Mori, M., Miura, Y., Nishiyama, N. and Ishii, H. Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects.
Cancer Med., 15, e72058 (2026) |
Ozaki, H., Sasaki, N. and Kitajima, S. An aminoacyl-tRNA synthetase governs dsRNA-mediated trade-off between longevity and innate immunity.
Mol. Cell, 86, 2237-2239 (2026) |
Kamakura, N., Jo, M., Takahashi, M. and Hirota, T. Targeting cell cycle vulnerabilities in cancers: Emerging strategies for therapeutic development.
Cancer Sci., in press (2026) |
Tanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Higo, H., Rai, K., Ichihara, E., Tomida, S., Hotta, K., Togashi, Y., Maeda, Y., Kiura, K., Katayama, R. and Ohashi, K. Afatinib overcomes osimertinib resistance via Egfr v804f mutation in a syngeneic Egfr-mutant lung cancer mouse model.
Cancer Sci., in press (2026) |
Nagasaka, M., Facchinetti, F., Bigot, L., Brayé, F., Groves, M. R., Yosa, J., Wekken, A. V., Aldea, M., Besse, B., Planchard, D., Naltet, C., Katayama, R., Olaussen, K. A., Loriot, Y. and Friboulet, L. The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
npj Precis. Oncol., in press (2026) |
Kurosaki, T., Suzuki, S., Watanabe, Y., Kenmotsu, H., Itoh, S., Yamaguchi, M., Shiono, A., Suzuki, T., Yokoyama, T., Toi, Y., Tanaka, H., Oki, M., Tsuda, T., Ichihara, E., Azuma, K., Tanaka, H., Arai, R., Uchibori, K., Miyauchi, E., Katayama, R. and Hayashi, H. Immune-related gene expression profiling and alectinib efficacy for patients with ALK-rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Lung Cancer, 216, 109416 (2026) |
